Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam
  NCT04353336		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    Chen
          NCT04384380    		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
    		21/12 inconclusive
      Gonzalez (HCQ)
              NCT04391127      		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
      		33/37 inconclusive
        HYCOVID
                  NCT04325893        		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
        		124/123 inconclusive
        • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
        NO COVID-19 (Lyngbakken)
                  NCT04316377        		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        		27/26 inconclusive
          ORCHID
                      NCT04332991          		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
          		242/237 inconclusive
          • inconclusive 2 % increase in clinical improvement,clinical improvement (14-day) (PE) with a high degree of certainty due to low risk of bias
          RECOVERY
                      NCT04381936          		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
          		1561/3155 safety concern
          • inconclusive 9 % increase in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
          SOLIDARITY (WHO study) HCQ
                      NCT04315948          		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
          		947/906 inconclusive
          • inconclusive 19 % increase in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
          TEACH
                      NCT04369742          		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
          		67/61 inconclusive
          • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
          • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 mild to moderate meta-analysis

          FACCT Trial
                      NCT04392973          		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
          		125/129 inconclusive
          • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine
                      NCT04322123          		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
          		221/227 safety concern
          • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 severe or critically meta-analysis

          HYDRA (Hernandez-Cardenas)
                      NCT04315896          		 RCThydroxychloroquineplaceboCOVID-19 severe or criticallysome concern
          		106/108 inconclusive
          • inconclusive 20 % decrease in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
          33 studies excluded by filtering options (18 RCT / 15 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons